Feb 12 (Reuters) - The U.S. Food and Drug Administration said on Thursday it has approved labeling changes to six menopause ...
The FDA approved changes to the labels for six menopausal hormone therapy products in a move the agency said clarifies risk ...
The new labeling for the products does not include risk statements related to cardiovascular disease, breast cancer and probable dementia, the agency said.
BridgeBio is hoping infigratinib will get another shot at approval after the medicine hit the key goals of a phase 3 study in ...
With the writing apparently on the wall, PTC Therapeutics has called off its latest bid for FDA approval of its Duchenne muscular dystrophy (DMD) drug Translarna.  | Late Thursday, PTC revealed that ...
Treatments for acquired hypothalamic obesity, dry eye disease, primary biliary cholangitis, psoriatic arthritis, and severe leukocyte adhesion deficiency-I under review.
Ultragenyx Pharmaceutical's employees were already braced for changes as the biopharma considered how to rebound from a pair ...
FDA drug alerts in pulmonology, including drug approvals/warnings, vaccine approvals, medical device recalls/updates, and drug label updates.